Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.

about

Temporal Trends in Survival and Healthcare Costs in Patients with Multiple Myeloma in the United States.

Item

http://www.wikidata.org/entity/Q52564578

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Temporal Trends in Survival an ...... Myeloma in the United States.

@en

Temporal Trends in Survival an ...... Myeloma in the United States.

@nl

type

Item

label

Temporal Trends in Survival an ...... Myeloma in the United States.

@en

Temporal Trends in Survival an ...... Myeloma in the United States.

@nl

prefLabel

Temporal Trends in Survival an ...... Myeloma in the United States.

@en

Temporal Trends in Survival an ...... Myeloma in the United States.

@nl

P1476

Temporal Trends in Survival an ...... Myeloma in the United States.

@en

P2093

Bong-Chul Chu

http://www.w3.org/2001/XMLSchema#string

Debra E Irwin

http://www.w3.org/2001/XMLSchema#string

Eric M Maiese

http://www.w3.org/2001/XMLSchema#string

Kristin A Evans

http://www.w3.org/2001/XMLSchema#string

P2860

Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.

Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

Cost effectiveness of pomalidomide in patients with relapsed and refractory multiple myeloma in Sweden.

Improved survival in multiple myeloma and the impact of novel therapies.

The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide mai

Multiple myeloma treatment transformed: a population-based study of changes in initial management approaches in the United States.

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients.

Real-world health care costs of relapsed/refractory multiple myeloma during the era of novel cancer agents.

Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.

P304

39-46

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29692879

http://www.w3.org/2001/XMLSchema#string

P932

5902764

http://www.w3.org/2001/XMLSchema#string